EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma

Xiaoting Wei, Zhengyun Zou, Weizhen Zhang, Meiyu Fang, Xiaoshi Zhang, Zhiguo Luo, Jing Chen, Gang Huang, Peng Zhang, Ying Cheng, Jiwei Liu, Jiyan Liu und 12 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114008 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Xiaoting Wei und 23 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hos…. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaHumansGTP PhosphohydrolasesImmunotherapyMembrane ProteinsMitogen-Activated Protein Kinase KinasesProgression-Free SurvivalPre-Registration Publication

Substanzen

GTP PhosphohydrolasesMembrane ProteinsMitogen-Activated Protein Kinase KinasesNRAS protein, human

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Research Institute, Beijing, China.
  • Comprehensive Cancer Center (word B7) of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
  • Department of Internal Medicine of Melanoma and Sarcoma, the Third People's Hospital of Zhengzhou, Henan, China.
  • Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
  • State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Zitieren

APA

Wei, X., Zou, Z., Zhang, W., Fang, M., Zhang, X., Luo, Z., Chen, J., Huang, G., Zhang, P., Cheng, Y., Liu, J., Liu, J., Zhang, J., Wu, D., Chen, Y., Ma, X., Pan, H., Jiang, R., Liu, X., …, & Si, L. (2024). A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114008

Vancouver

Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, et al. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114008

BibTeX
@article{Wei2024,
  author = {Wei, Xiaoting and Zou, Zhengyun and Zhang, Weizhen and Fang, Meiyu and Zhang, Xiaoshi and Luo, Zhiguo and Chen, Jing and Huang, Gang and Zhang, Peng and Cheng, Ying and Liu, Jiwei and Liu, Jiyan and Zhang, Junping and Wu, Di and Chen, Yu and Ma, Xiaobiao and Pan, Hongming and Jiang, Renbing and Liu, Xinlan and Ren, Xiubao and Tian, Hongqi and Jia, Zhongwei and Guo, Jun and Si, Lu},
  title = {A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114008}
}
Kostenlos starten →